MétaCan
Menu
Back to cohort
Record W3038245647 · doi:10.1111/ajt.16174

Phase 3 trial of human islet-after-kidney transplantation in type 1 diabetes

2020· article· en· W3038245647 on OpenAlexafffund
James F. Markmann, Michael R. Rickels, Thomas L. Eggerman, Nancy D. Bridges, David E. Lafontant, Julie C. Qidwai, Eric D. Foster, William R. Clarke, Malek Kamoun, Rodolfo Alejandro, Melena D. Bellin, Kathryn Chaloner, Christine W. Czarniecki, Julia Goldstein, Bernhard J. Hering, Lawrence G. Hunsicker, Dixon B. Kaufman, Olle Korsgren, Christian P. Larsen, Xunrong Luo, Ali Naji, José Oberholzer, Andrew M. Posselt, Camillo Ricordi, Peter Senior, A. M. James Shapiro, Peter G. Stock, Nicole A. Turgeon

Bibliographic record

VenueAmerican Journal of Transplantation · 2020
Typearticle
Languageen
FieldMedicine
TopicPancreatic function and diabetes
Canadian institutionsUniversity of Alberta
FundersNational Center for Advancing Translational SciencesNational Institute of Allergy and Infectious DiseasesUniversity of Illinois at ChicagoUniversity of Illinois at Urbana-ChampaignUppsala UniversitetUniversity of MinnesotaUniversity of California, San FranciscoNovo Nordisk FondenNorthwestern UniversityUniversity of AlbertaDeutsches KrebsforschungszentrumEmory UniversityNational Center for Research ResourcesUniversity of PennsylvaniaGeorgia Clinical and Translational Science AllianceNational Institute of Diabetes and Digestive and Kidney DiseasesUniversity of IowaUniversity of Miami
KeywordsMedicineType 1 diabetesHypoglycemiaTransplantationDiabetes mellitusIsletType 2 diabetesInternal medicineClinical endpointInsulinRandomized controlled trialKidney transplantationIntensive care medicineSurgeryEndocrinology

Abstract

fetched live from OpenAlex

Allogeneic islet transplant offers a minimally invasive option for β cell replacement in the treatment of type 1 diabetes (T1D). The CIT consortium trial of purified human pancreatic islets (PHPI) in patients with T1D after kidney transplant (CIT06), a National Institutes of Health–sponsored phase 3, prospective, open-label, single-arm pivotal trial of PHPI, was conducted in 24 patients with impaired awareness of hypoglycemia while receiving intensive insulin therapy. PHPI were manufactured using standardized processes. PHPI transplantation was effective with 62.5% of patients achieving the primary endpoint of freedom from severe hypoglycemic events and HbA 1c ≤ 6.5% or reduced by ≥ 1 percentage point at 1 year posttransplant. Median HbA 1c declined from 8.1% before to 6.0% at 1 year and 6.3% at 2 and 3 years following transplant ( P < .001 for all vs baseline), with related improvements in hypoglycemia awareness and glucose variability. The improved metabolic control was associated with better health-related and diabetes-related quality of life. The procedure was safe and kidney allograft function remained stable after 3 years. These results add to evidence establishing allogeneic islet transplant as a safe and effective treatment for patients with T1D and unstable glucose control despite intensive insulin treatment, supporting the indication for PHPI in the post–renal transplant setting.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.007
Threshold uncertainty score0.022

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.001
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0040.003
Bibliometrics0.0000.000
Science and technology studies0.0010.002
Scholarly communication0.0020.001
Open science0.0010.001
Research integrity0.0020.007
Insufficient payload (model declined to judge)0.0070.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.018
GPT teacher head0.296
Teacher spread0.278 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations108
Published2020
Admission routes2
Has abstractno

Explore more

Same venueAmerican Journal of TransplantationSame topicPancreatic function and diabetesFrench-language works237,207